Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Abbott announced commercial availability of its next-generation Oncodetect molecular residual disease test, a tumor-informed whole-genome sequencing blood test that detects circulating tumor DNA during and after cancer treatment. The test tracks up to 5,000 patient-specific variants versus 200 in the first generation, uses MAESTRO technology (developed at the Broad Institute and enhanced by Abbott) to enrich tumor DNA up to ~1,000-fold, and achieves a limit of detection below one part per million with >99% analytical specificity.
Key figures
- Drug Name
- Oncodetect (next-generation MRD test)
- Variants tracked
- up to 5,000 patient-specific variants (vs up to 200 first-generation)
- Limit of detection
- below one part per million (30-fold improvement)
- Tumor dna enrichment
- ~1,000-fold
- Analytical specificity
- >99%
- Addressable us patients
- more than 3 million with solid tumors (internal estimate)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.